Patrick J. McKiernan, Armando Ganoza, James E. Squires, Robert H. Squires, Jerry Vockley, George Mazariegos, Kyle Soltys, Qing Sun, Rakesh Sindhi – 12 February 2019 – Indications for liver transplantation (LT) in metabolic disease are evolving. We reviewed the US experience with primary LT for metabolic disease in the Scientific Registry for Transplant Recipients (October 1987 to June 2017) to determine the following: temporal changes in indications, longterm outcomes, and factors predicting survival.

Jingjing Tong, Cui‐Juan Han, Jia‐Zhen Zhang, Wen‐Zhi He, Guo‐Jun Zhao, Xu Cheng, Lei Zhang, Ke‐Qiong Deng, Ye Liu, Hui‐Fen Fan, Song Tian, Jingjing Cai, Zan Huang, Zhi‐Gang She, Peng Zhang, Hongliang Li – 12 February 2019 – Nonalcoholic fatty liver disease (NAFLD) has become a worldwide epidemic. A large and growing unmet therapeutic need has inspired numerous studies in the field.

Martijn C.G.J. Brouwers, Nynke Simons, Coen D.A. Stehouwer, Ger H. Koek, Nicolaas C. Schaper, Aaron Isaacs – 11 February 2019 – Coronary artery disease (CAD) is the principal cause of death in patients with nonalcoholic fatty liver disease (NAFLD). The aim of the present study was to investigate whether NAFLD is causally involved in the pathogenesis of CAD.

Paula C. Zimbrean, Geliang Gan, Yanhong Deng, Sukru Emre – 11 February 2019 – Body image (BI) concerns have been reported to play a significant role in the psychological adaptation after organ transplantation. There is a paucity of data about BI beliefs in liver transplant recipients. We report the results of a cross‐sectional study of 177 liver transplant recipients for whom we assessed BI, anxiety, depression, and quality of life (QOL) using validated instruments. Our results indicate that higher BI concerns correlated with higher levels of anxiety and depression.

Nima Memaran, Bianca Borchert‐Mörlins, Bernhard M. W. Schmidt, Rizky I. Sugianto, Hannes Wilke, Ricarda Blöte, Ulrich Baumann, Elena Bauer, Anika von Wick, Norman Junge, Christoph Leiskau, Eva D. Pfister, Daniela Thurn‐Valsassina, Nicolas Richter, Imeke Goldschmidt, Anette Melk – 11 February 2019 – Cardiovascular (CV) events account for 8%‐13% of deaths after liver transplantation (LT) in adulthood. Although CV risk factors (RFs) are present, little is known about the prevalence of subclinical CV target organ damage (TOD) in children after LT.

Mattias Mandorfer, Manfred Hecking – 11 February 2019

Ana I. Álvarez‐Mercado, José Gulfo, Manuel Romero Gómez, Mónica B. Jiménez‐Castro, Jordi Gracia‐Sancho, Carmen Peralta – 10 February 2019 – In the field of liver transplantation, the demand for adequate allografts greatly exceeds the supply. Therefore, expanding the donor pool to match the growing demand is mandatory. The present review summarizes current knowledge of the pathophysiology of ischemia/reperfusion injury in steatotic grafts, together with recent pharmacological approaches aimed at maximizing the utilization of these livers for transplantation.

Priyankar Dey – 8 February 2019

Maria‐Angélica Salinas Nova, Ángela Rojas Meneses, Juan‐Carlos Restrepo Gutierrez – 8 February 2019 – Liver transplantation began in Colombia in 1979. It is one of the most active countries in this field in Latin America but has faced problems with the regulation and appropriate management of solid organ transplantations, including transplant tourism, which is a worldwide problem. There is a well‐structured donation and transplant network regulated by the government in all the stages of the process.

Akira Honda, Atsushi Tanaka, Tetsuji Kaneko, Atsumasa Komori, Masanori Abe, Mie Inao, Tadashi Namisaki, Naoaki Hashimoto, Kazuhito Kawata, Atsushi Takahashi, Masashi Ninomiya, Jong‐Hon Kang, Mie Arakawa, Satoshi Yamagiwa, Satoru Joshita, Takeji Umemura, Ken Sato, Akira Kaneko, Kentaro Kikuchi, Jun Itakura, Takako Nomura, Keisuke Kakisaka, Hideki Fujii, Norifumi Kawada, Yasuhiro Takikawa, Tsutomu Masaki, Hiromasa Ohira, Satoshi Mochida, Hitoshi Yoshiji, Satoshi Iimuro, Yasushi Matsuzaki, Hajime Takikawa, Japan PBC Study Group – 8 February 2019 – In Japan, bezafibrate (BF) is a second‐line ag